A big part of Biogen's efforts to defend its spinal muscular atrophy (SMA) business has been dealt a setback by the FDA, which declined to approve a high-dose version of its flagship Spinraza product.

Only 2-5% of all US patients are enrolled in a clinical trial. At the same time, at least 85% of clinical trials fail to meet their recruitment goals, nearly half under-enrol patients, and a striking ...

The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme. Presented at the ...

Amit Etkin, Alto's founder, president, and CEO. NYSE-listed Alto Neuroscience has raised $120 million in a private placement that will be used to advance its recently acquired candidate for ...

MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff has continued with a $6.7 billion bid to acquire Terns Pharma. The Financial Times first reported that talks between the ...

Novo Nordisk has reported the first mid-stage clinical data with its triple G agonist for diabetes in China, as it starts an international trials programme. The drug candidate, UBT251, acts on GLP-1, ...

A patient advocacy group in the UK is calling for changes to the decade-old meningitis vaccination programme, after an outbreak in Kent that has killed two young people and left nearly a dozen others ...

In Philadelphia this month, Editor in Chief Jonah Comstock spoke with Craig Ackerman, a partner at the Alexander Group, about ...

President Donald Trump has signed an executive order imposing tariffs of up to 100% on imported brandname medicines, unless ...

Each year, World Bipolar Day is an opportunity to raise awareness and deepen understanding of bipolar disorder, a condition ...

Routine genomic testing could correct well-established disparities in breast cancer survival rates between white and Black women, according to a new study. Black women have a 5% lower incidence of ...

Merck KGaA has teamed up with Flagship Pioneering's Valo Health on an ambitious project to apply AI to the discovery of novel drug targets and therapeutics for Parkinson's disease. The partnership ...